Marker Therapeutics (MRKR) Receivables - Other (2018 - 2025)
Marker Therapeutics (MRKR) has disclosed Receivables - Other for 7 consecutive years, with $1.7 million as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Other rose 123.69% to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 123.69% increase, with the full-year FY2024 number at $2.3 million, up 128.32% from a year prior.
- Receivables - Other was $1.7 million for Q3 2025 at Marker Therapeutics, down from $1.7 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $2.5 million in Q2 2024 to a low of $237.0 in Q4 2021.
- A 5-year average of $1.2 million and a median of $1.0 million in 2023 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: crashed 99.98% in 2021, then surged 1013403.8% in 2022.
- Marker Therapeutics' Receivables - Other stood at $237.0 in 2021, then soared by 1013403.8% to $2.4 million in 2022, then crashed by 57.21% to $1.0 million in 2023, then soared by 128.32% to $2.3 million in 2024, then dropped by 29.04% to $1.7 million in 2025.
- Per Business Quant, the three most recent readings for MRKR's Receivables - Other are $1.7 million (Q3 2025), $1.7 million (Q2 2025), and $2.5 million (Q1 2025).